Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
PolyPeptide Group AG ( (CH:PPGN) ) just unveiled an update.
PolyPeptide Group AG reported preliminary, unaudited results showing strong top-line expansion in 2025, with revenue rising around 15.6% year-on-year to approximately EUR 389 million, mainly driven by demand in metabolic therapeutics and rapid growth in the GLP-1 segment. Profitability improved markedly, with EBITDA margin increasing from 7.5% in 2024 to between 11–12%, supported by better execution across its multi-site network and successful ramp-up of large-scale peptide manufacturing capacity in Belgium. Capital expenditure for the year came in just above EUR 100 million, while stronger operating cash flow and an expanded revolving credit facility left the group with EUR 75 million in cash and a further EUR 51 million in undrawn committed credit at year-end, bolstering financial flexibility. On the back of this momentum, the company reaffirmed its mid-term ambitions to double 2023 revenue by 2028 and lift EBITDA margin to about 25%, underscoring its bid to solidify its position as a key CDMO player in the high-growth peptide market.
The most recent analyst rating on (CH:PPGN) stock is a Sell with a CHF27.00 price target. To see the full list of analyst forecasts on PolyPeptide Group AG stock, see the CH:PPGN Stock Forecast page.
More about PolyPeptide Group AG
PolyPeptide Group AG is a specialized global contract development and manufacturing organization (CDMO) focused on peptide- and oligonucleotide-based active pharmaceutical ingredients for pharma and biotech customers. Serving a fast-growing market with significant exposure to metabolic diseases, including GLP-1 therapies, the company operates six GMP-certified facilities across Europe, the U.S. and India and supports projects from early-stage development through to commercial supply.
Average Trading Volume: 47,655
Technical Sentiment Signal: Buy
Current Market Cap: CHF934.8M
Learn more about PPGN stock on TipRanks’ Stock Analysis page.